GLP-1 Drugs: The Promises and the Troubling Side Effects Nobody Told You About

More than 30 million Americans are now taking GLP-1 drugs — medications like Ozempic, Wegovy, and Zepbound that were originally approved for diabetes but have transformed into the most talked-about weight loss treatment in a generation. The results for many users have been life-changing. But a growing body of research — and thousands of lawsuits — reveal a darker side of these drugs that patients deserve to understand before they start.

This is an important topic in our Health & Lifestyle coverage at TheTrendsWire.

*Note: This article is for informational purposes. Always consult your doctor before starting, stopping, or changing any medication.*

What GLP-1 Drugs Are — and Why Everyone Is Taking Them

GLP-1 (glucagon-like peptide-1) receptor agonists were first approved by the FDA in 2005 as a treatment for Type 2 diabetes. Researchers soon noticed something unexpected: patients were also losing significant amounts of weight. That discovery triggered a pharmaceutical revolution.

There are now more than a dozen approved GLP-1 drugs, including:

• Semaglutide — sold as Ozempic (diabetes) and Wegovy (weight loss)

• Tirzepatide — sold as Mounjaro (diabetes) and Zepbound (weight loss)

• Liraglutide — sold as Victoza (diabetes) and Saxenda (weight loss)

The drugs work by mimicking the natural GLP-1 hormone, which regulates blood sugar and appetite. They slow digestion, reduce hunger, and increase feelings of fullness. Most users lose at least 5% of their body weight — many lose significantly more.

For users like Carly Anderson — who told CBS News she could "literally feel inflammation leave her body" within three hours of her first dose — these drugs have delivered transformative results. Her joint pain disappeared. Her mile time dropped by a full minute.

The Troubling Side Effects

The benefits are real. So are the risks. Here is what the research — and more than 4,000 lawsuits filed against GLP-1 manufacturers — is revealing:

1. Gastrointestinal problems — the most common

Nausea, vomiting, diarrhoea, and constipation affect the majority of users, particularly at the start. For most, these ease over time. But for some, the effects are severe — including gastroparesis (stomach paralysis), where the stomach stops emptying normally. In rare cases, this requires hospitalization.

2. Muscle loss (Sarcopenia)

Studies consistently show that GLP-1 users lose not just fat but significant lean muscle mass. Yale endocrinologist Dr. Ania Jastreboff recommends weight-bearing exercise to mitigate this — but the risk is real, especially for older patients for whom muscle loss accelerates aging-related health decline. "Ozempic face" — the drawn, gaunt appearance some users develop — is a visible consequence of this muscle and fat loss.

3. Mental health concerns — depression and suicidal thoughts

One of the most alarming findings from a University of Pennsylvania AI analysis of 410,000 Reddit posts from GLP-1 users: patients have reported significant mental health side effects including depression and suicidal thoughts, which may not be fully captured in clinical trials. The drugs appear to engage the hypothalamus — which regulates a wide variety of hormones — in ways that are not yet fully understood.

4. Vision loss

A rare but serious eye condition called ischemic optic neuropathy — which can cause sudden or partial vision loss — has been linked to GLP-1 use in recent research. The FDA is actively reviewing this data.

5. Weight regain — faster than before

A British Medical Journal study found that people who stop taking GLP-1 drugs regain weight approximately four times faster than weight regained after traditional diet and exercise programs. This raises serious questions about the long-term dependency these drugs create — and the consequences of stopping.

6. Online access risks

An investigation by KFF Health News found that GLP-1 drugs are dangerously easy to obtain online through telehealth platforms — with some patients receiving prescriptions and injections within 24 hours, without adequate medical supervision. One patient was hospitalized within 24 hours of her first dose after obtaining medication through a telehealth service.

7. Eating disorder risk

Researchers have flagged concerns that GLP-1s' powerful appetite-suppression effects could exacerbate existing eating disorders or potentially trigger new cases — including anorexia — particularly in younger users.

Who Should Be Cautious

GLP-1 drugs are not for everyone. According to WHO guidelines, they are recommended only for adults with a BMI of 30 or above, or 27 with metabolic conditions like diabetes. They are not recommended for pregnant women — the potential impact on fetal development has not been adequately studied.

The FDA requires GLP-1 prescriptions for weight loss to be used alongside calorie restriction and increased exercise. Getting these medications online — without proper medical supervision — significantly increases risk.

Key Takeaways

• Over 30 million Americans are on GLP-1 drugs — originally approved for diabetes, now widely used for weight loss.

• GLP-1 drugs are highly effective for weight loss but carry serious side effects including gastrointestinal problems, muscle loss, depression, vision loss, and rapid weight regain when stopped.

• A University of Pennsylvania study of 410,000 Reddit posts found patients reporting depression and suicidal thoughts not captured in clinical trials.

• 4,000+ lawsuits have been filed against GLP-1 manufacturers over gastrointestinal and other injuries.

• BMJ research found patients who stop GLP-1s regain weight 4x faster than after traditional programs.

• Online access without supervision is dangerous — one patient was hospitalized within 24 hours of her first dose from a telehealth prescription.

• Always consult your doctor — these are powerful medications that require proper medical oversight.

*If you are experiencing mental health concerns, please reach out to a healthcare provider or call the 988 Suicide and Crisis Lifeline by dialing or texting 988.*